Physician profile
James E Saxton
NPI 1477645547
$2,077.60
in general payments reported to CMS, 2019-2025
17 companies · $85.12 in 2025
The $85.12 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $256 · 2021: $312 · 2022: $147 · 2023: $290 · 2024: $336 · 2025: $85.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $792.15 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $403.08 | 2019-2024 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $185.25 | 2019-2021 | |
| Pfizer INC. | $181.84 | 2019-2021 | |
| Lilly USA, LLC | $166.31 | 2019-2024 | Mounjaro, Zepbound |
| Allergan, INC. | $51.95 | 2019-2020 | |
| Astellas Pharma US INC | $50.58 | 2019 | |
| Mylan Specialty L.P. | $36.60 | 2022-2023 | Yupelri |
| Novo Nordisk INC | $31.78 | 2022 | |
| Idorsia Pharmaceuticals US INC | $29.52 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $27.24 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $25.26 | 2020 | |
| Almatica Pharma LLC | $24.62 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.58 | 2019-2021 | |
| Amgen INC. | $17.17 | 2025 | Repatha, Otezla |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $15.07 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.60 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Saxton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.